论文部分内容阅读
目的：探讨术后早期应用肠内高营养治疗对晚期胃癌患者白细胞介素（IL）-2系统水平的影响。方法：98例晚期胃癌术后患者随机分成早期肠内高营养组和常规输液对照组，采用酶联免疫吸附测定（ELISA）等方法检测两组患者治疗前后的外周血清IL－2、IL－2受体（IL－2R）α及可溶性IL－2R（sIL－2R）水平。结果：早期肠内高营养组患者冶疗1周后，机体IL－2和IL－2Rα水平较治疗前显著上升，sIL－2R水平明显下降（治疗前：IL－224.83U／ml±2.10U／ml，IL－2Rα17.8％±2．8％，sIL－2R347．9U／ml±57．8U／ml，治疗后：IL－279．82U／ml±6．88U／ml，IL－2Rα27．5％±4．0％，sIL－2R157．9U／ml±24．3U／ml）；而常规输液对照组患者的IL－2水平较治疗前呈下降趋势，IL－2Rα和sIL－2R水平变化不明显（治疗前：IL－221.87U／ml±1．98U／ml，IL－2Rα18．3％±3.8％，sIL－2R479．3U／ml±69．8U／ml；治疗后：IL－211．34U／ml±0．89U／ml，IL－2Rα17．4％±2．7％，sIL－2R481．2U／ml±70.4U／ml），两组治疗后结果相比有显著差异。结论：早期应用肠内高营养治疗晚期胃癌术后患者，有利于尽快恢复患者的机体免疫调节功能，为今后临床开展该项治疗提供了证据。
Objective: To investigate the effect of early postoperative enteral nutrition on the interleukin (IL) -2 system level in patients with advanced gastric cancer. Methods: Ninety-eight patients with advanced gastric cancer were randomly divided into early enteral hyper-nutrition group and conventional infusion control group. Peripheral serum IL-2 and IL-2 levels were measured before and after treatment in two groups of patients by enzyme-linked immunosorbent assay (ELISA). Receptor (IL-2R) alpha and soluble IL-2R (sIL-2R) levels. Results: After 1 week of treatment in patients with early enteral hypernutrition, the levels of IL-2 and IL-2Rα increased significantly and the levels of sIL-2R decreased significantly before treatment (before treatment: IL-224.83 U/ml±2.10 U/ Ml,IL-2Rα17.8%±2.8%,sIL-2R347.9U/ml±57.8U/ml,after treatment: IL-279.82U/ml±6.88U/ml,IL-2Rα27.5 %±4.0%, sIL-2R157.9U/ml±24.3U/ml); while the IL-2 level in the conventional infusion control group showed a decreasing trend compared with that before treatment, and IL-2Rα and sIL-2R levels did not change. Significantly (before treatment: IL-221.87 U/ml ± 1.98 U/ml, IL-2Rα 18.3% ± 3.8%, sIL-2R 479.3 U/ml ± 69.8 U/ml; after treatment: IL-211.34U /ml ± 0.89 U/ml, IL-2Rα 17.4% ± 2.7%, sIL-2R 481.2 U/ml ± 70.4 U/ml). There was a significant difference between the two groups after treatment. Conclusion: Early application of enteral nutrition in the treatment of advanced gastric cancer patients is beneficial to restore the body’s immune function as soon as possible, providing evidence for the clinical development of the treatment.